With Generous Partner Abbott Back For More, Reata Aims High Again
This article was originally published in Start Up
Executive Summary
Texas biotech Reata can add another $400 million license deal, its second with Abbott, to the $178 million it has raised from venture backers. But this time it's for preclinical assets.